The consequences of enhanced cell-autonomous glucose metabolism

Trends in Endocrinology and Metabolism

Volumn 23, Issue 11, 2012, Pages 545-551

  Locasale, Jason W ^a  

^a Department of Obstetrics Gynecology   (United States)

Author keywords

Cancer metabolism; Cell growth; Glycolysis; Redox status; Systems biology; Warburg effect

Indexed keywords

GLUCOSE; LACTIC ACID;

ARTICLE; BIOMASS; CARBOHYDRATE INTAKE; ENERGY METABOLISM; GENETIC CONSERVATION; GLUCOSE METABOLISM; GLUCOSE TRANSPORT; HUMAN; PHYSICAL CHEMISTRY; PRIORITY JOURNAL; REGULATORY MECHANISM;

ANIMALS; BIOLOGICAL TRANSPORT; CELL TRANSFORMATION, NEOPLASTIC; GLUCOSE; GLYCOLYSIS; HUMANS; LACTIC ACID; NEOPLASMS; OXIDATION-REDUCTION; SIGNAL TRANSDUCTION;

EID: 84867142346     PISSN: 10432760     EISSN: 18793061     Source Type: Journal    
DOI: 10.1016/j.tem.2012.07.005     Document Type: Article

References (68)

1. Pollak M. Insulin and insulin-like growth factor signalling in neoplasia. Nat. Rev. Cancer 2008, 8:915-928.
2. Taubes G. Unraveling the obesity-cancer connection. Science 2012, 335:286.
3. Pollak M. The insulin and insulin-like growth factor receptor family in neoplasia: an update. Nat. Rev. Cancer 2012, 12:159-169.
4. Engelman J.A., et al. The evolution of phosphatidylinositol 3-kinases as regulators of growth and metabolism. Nat. Rev. Genet. 2006, 7:606-619.
5. Levine A.J., Puzio-Kuter A.M. The control of the metabolic switch in cancers by oncogenes and tumor suppressor genes. Science 2010, 330:1340-1344.
6. Ward P.S., Thompson C.B. Metabolic reprogramming: a cancer hallmark even warburg did not anticipate. Cancer Cell 2012, 21:297-308.
7. Deberardinis R.J., et al. The biology of cancer: metabolic reprogramming fuels cell growth and proliferation. Cell Metab. 2008, 7:11-20.
8. Le A., et al. Inhibition of lactate dehydrogenase A induces oxidative stress and inhibits tumor progression. Proc. Natl. Acad. Sci. U.S.A. 2010, 107:2037-2042.
9. Vander Heiden M.G., et al. Metabolic pathway alterations that support cell proliferation. Cold Spring Harb. Symp. Quant. Biol. 2011, 76:325-334.
10. Warburg O., et al. Ueber den Stoffwechsel der Tumoren. Biochemische Zeitschrift 1924, 152:319-344. (in German).
11. Warburg O., et al. The metabolism of tumors in the body. J. Gen. Physiol. 1927, 8:519-530.
12. Locasale J.W., Cantley L.C. Metabolic flux and the regulation of mammalian cell growth. Cell Metab. 2011, 14:443-451.
13. Lehninger A.L., et al. Principles of Biochemistry 1993, Worth Publishers.
14. Vander Heiden M.G., et al. Understanding the Warburg effect: the metabolic requirements of cell proliferation. Science 2009, 324:1029-1033.
15. Cairns R.A., et al. Regulation of cancer cell metabolism. Nat. Rev. Cancer 2011, 11:85-95.
16. Anastasiou D., et al. Inhibition of pyruvate kinase M2 by reactive oxygen species contributes to cellular antioxidant responses. Science 2011, 334:1278-1283.
17. Kruger N.J., von Schaewen A. The oxidative pentose phosphate pathway: structure and organisation. Curr. Opin. Plant Biol. 2003, 6:236-246.
18. +/NADPH ratios. Biochem. Biophys. Res. Commun. 1976, 68:436-441.
19. Eggleston L.V., Krebs H.A. Regulation of the pentose phosphate cycle. Biochem. J. 1974, 138:425-435.
20. Ying H., et al. Oncogenic Kras maintains pancreatic tumors through regulation of anabolic glucose metabolism. Cell 2012, 149:656-670.
21. Racker E., et al. Glycolysis and methylaminoisobutyrate uptake in rat-1 cells transfected with ras or myc oncogenes. Proc. Natl. Acad. Sci. U.S.A. 1985, 82:3535-3538.
22. Flier J.S., et al. Elevated levels of glucose transport and transporter messenger RNA are induced by ras or src oncogenes. Science 1987, 235:1492-1495.
23. Yun J., et al. Glucose deprivation contributes to the development of KRAS pathway mutations in tumor cells. Science 2009, 325:1555-1559.
24. Boros L.G., et al. Nonoxidative pentose phosphate pathways and their direct role in ribose synthesis in tumors: is cancer a disease of cellular glucose metabolism?. Med. Hypotheses 1998, 50:55-59.
25. Vizan P., et al. K-ras codon-specific mutations produce distinctive metabolic phenotypes in human fibroblasts. Cancer Res. 2005, 65:5512-5515.
26. Liu H.B., et al. Fructose induces transketolase flux to promote pancreatic cancer growth. Cancer Res. 2010, 70:6368-6376.
27. Chandel N.S., Budinger G.R.S. The cellular basis for diverse responses to oxygen. Free Radic. Biol. Med. 2007, 42:165-174.
28. Wellen K.E., Thompson C.B. A two-way street: reciprocal regulation of metabolism and signalling. Nat. Rev. Mol. Cell Biol. 2012, 13:U270-U271.
29. Droge W. Free radicals in the physiological control of cell function. Physiol. Rev. 2002, 82:47-95.
30. Karisch R., et al. Global proteomic assessment of the classical protein-tyrosine phosphatome and 'redoxome'. Cell 2011, 146:826-840.
31. Cooper C.E., et al. Nanotransducers in cellular redox signaling: modification of thiols by reactive oxygen and nitrogen species. Trends Biochem. Sci. 2002, 27:489-492.
32. Leslie N.R. The redox regulation of PI 3-kinase-dependent signaling. Antioxid. Redox Signal. 2006, 8:1765-1774.
33. 2. J. Biol. Chem. 2002, 277:20336-20342.
34. Trachootham D., et al. Redox regulation of cell survival. Antioxid. Redox Signal. 2008, 10:1343-1374.
35. Christofk H.R., et al. The M2 splice isoform of pyruvate kinase is important for cancer metabolism and tumour growth. Nature 2008, 452:230-233.
36. Gruning N.M., et al. Pyruvate kinase triggers a metabolic feedback loop that controls redox metabolism in respiring cells. Cell Metab. 2011, 14:415-427.
37. Kensler T.W., et al. Cell survival responses to environmental stresses via the Keap1-Nrf2-ARE pathway. Annu. Rev. Pharmacol. Toxicol. 2007, 47:89-116.
38. Luo J., et al. Principles of cancer therapy: oncogene and non-oncogene addiction. Cell 2009, 136:823-837.
39. De Raedt T., et al. Exploiting cancer cell vulnerabilities to develop a combination therapy for Ras-driven tumors. Cancer Cell 2012, 20:400-413.
40. +-NADH ratio in normal and transformed fibroblasts. J. Biol. Chem. 1974, 249:4138-4143.
41. Vander Heiden M.G., et al. Evidence for an alternative glycolytic pathway in rapidly proliferating cells. Science 2010, 329:1492-1499.
42. Haigis M.C., Guarente L.P. Mammalian sirtuins - emerging roles in physiology, aging, and calorie restriction. Genes Dev. 2006, 20:2913-2921.
43. Beard D.A., Qian H. Relationship between thermodynamic driving force and one-way fluxes in reversible processes. PLoS ONE 2007, 2:4.
44. Hill T.L., Chay T.R. Theoretical methods for study of kinetics of models of the mitochondrial respiratory chain. Proc. Natl. Acad. Sci. U.S.A. 1979, 76:3203-3207.
45. Qian H., Beard D.A. Thermodynamics of stoichiometric biochemical networks in living systems far from equilibrium. Biophys. Chem. 2005, 114:213-220.
46. Qian H., et al. Stoichiometric network theory for nonequilibrium biochemical systems. Eur. J. Biochem. 2003, 270:415-421.
47. de Koning T.J., et al. L-serine in disease and development. Biochem. J. 2003, 371:653-661.
48. Kalhan S.C., Hanson R.W. Resurgence of serine: an often neglected but indispensable amino acid. J. Biol. Chem. 2012, 287:19786-19791.
49. Possemato R., et al. Functional genomics reveal that the serine synthesis pathway is essential in breast cancer. Nature 2011, 476:346-350.
50. Locasale J.W., et al. Phosphoglycerate dehydrogenase diverts glycolytic flux and contributes to oncogenesis. Nat. Genet. 2011, 43:869-874.
51. Westfall P.J., et al. Stress resistance and signal fidelity independent of nuclear MAPK function. Proc. Natl. Acad. Sci. U.S.A. 2008, 105:12212-12217.
52. Umbarger H.E. Amino acid biosynthesis and its regulation. Annu. Rev. Biochem. 1978, 47:532-606.
53. Pawson T. Specificity in signal transduction: from phosphotyrosine-SH2 domain interactions to complex cellular systems. Cell 2004, 116:191-203.
54. Mann M., Jensen O.N. Proteomic analysis of post-translational modifications. Nat. Biotechnol. 2003, 21:255-261.
55. Zee B.M., et al. In vivo residue-specific histone methylation dynamics. J. Biol. Chem. 2011, 285:3341-3350.
56. Cheung P., et al. Signaling to chromatin through histone modifications. Cell 2000, 103:263-271.
57. Jenuwein T., Allis C.D. Translating the histone code. Science 2001, 293:1074-1080.
58. Bennett B.D., et al. Absolute metabolite concentrations and implied enzyme active site occupancy in Escherichia coli. Nat. Chem. Biol. 2009, 5:593-599.
59. Cai L., et al. Acetyl-CoA induces cell growth and proliferation by promoting the acetylation of histones at growth genes. Mol. Cell 2011, 42:426-437.
60. Teperino R., et al. Histone methyl transferases and demethylases; can they link metabolism and transcription?. Cell Metab. 2010, 12:321-327.
61. Katada S., et al. Connecting threads: epigenetics and metabolism. Cell 2012, 148:24-28.
62. Peng C., et al. The first identification of lysine malonylation substrates and its regulatory enzyme. Mol. Cell. Proteomics 2011, 10:12.
63. Tan M.J., et al. Identification of 67 histone marks and histone lysine crotonylation as a new type of histone modification. Cell 2011, 146:1015-1027.
64. Hamanaka R.B., Chandel N.S. Targeting glucose metabolism for cancer therapy. J. Exp. Med. 2012, 209:211-215.
65. Vander Heiden M.G. Targeting cancer metabolism: a therapeutic window opens. Nat. Rev. Drug Discov. 2011, 10:671-684.
66. Edwards J.S., et al. In silico predictions of Escherichia coli metabolic capabilities are consistent with experimental data. Nat. Biotechnol. 2001, 19:125-130.
67. Shlomi T., et al. Genome-scale metabolic modeling elucidates the role of proliferative adaptation in causing the Warburg effect. PLoS Comput. Biol. 2011, 7:8.
68. Imielinski M., Belta C. Deep epistasis in human metabolism. Chaos 2010, 20:026104.